These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner. Tudor D; Bomsel M AIDS; 2011 Mar; 25(6):751-9. PubMed ID: 21330910 [TBL] [Abstract][Full Text] [Related]
5. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors. Ortiz DF; Lansing JC; Rutitzky L; Kurtagic E; Prod'homme T; Choudhury A; Washburn N; Bhatnagar N; Beneduce C; Holte K; Prenovitz R; Child M; Killough J; Tyler S; Brown J; Nguyen S; Schwab I; Hains M; Meccariello R; Markowitz L; Wang J; Zouaoui R; Simpson A; Schultes B; Capila I; Ling L; Nimmerjahn F; Manning AM; Bosques CJ Sci Transl Med; 2016 Nov; 8(365):365ra158. PubMed ID: 27856797 [TBL] [Abstract][Full Text] [Related]
6. Fcγ Receptor Function and the Design of Vaccination Strategies. Bournazos S; Ravetch JV Immunity; 2017 Aug; 47(2):224-233. PubMed ID: 28813656 [TBL] [Abstract][Full Text] [Related]
7. The Immunological Organ Environment Dictates the Molecular and Cellular Pathways of Cytotoxic Antibody Activity. Gordan S; Albert H; Danzer H; Lux A; Biburger M; Nimmerjahn F Cell Rep; 2019 Dec; 29(10):3033-3046.e4. PubMed ID: 31801071 [TBL] [Abstract][Full Text] [Related]
8. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730 [TBL] [Abstract][Full Text] [Related]
9. IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs. Boesch AW; Miles AR; Chan YN; Osei-Owusu NY; Ackerman ME MAbs; 2017 Apr; 9(3):455-465. PubMed ID: 28055295 [TBL] [Abstract][Full Text] [Related]
10. Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation. Mimura Y; Mimura-Kimura Y; Saldova R; Rudd PM; Jefferis R Front Immunol; 2022; 13():818382. PubMed ID: 35154135 [TBL] [Abstract][Full Text] [Related]
11. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058 [TBL] [Abstract][Full Text] [Related]
12. The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo. Anthony RM; Nimmerjahn F Curr Opin Organ Transplant; 2011 Feb; 16(1):7-14. PubMed ID: 21150612 [TBL] [Abstract][Full Text] [Related]
13. Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity. Yu X; Menard M; Prechl J; Bhakta V; Sheffield WP; Lazarus AH Blood; 2016 Jan; 127(1):132-8. PubMed ID: 26500340 [TBL] [Abstract][Full Text] [Related]
14. The role of Fc-FcγR interactions in IgG-mediated microbial neutralization. Bournazos S; DiLillo DJ; Ravetch JV J Exp Med; 2015 Aug; 212(9):1361-9. PubMed ID: 26282878 [TBL] [Abstract][Full Text] [Related]
15. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs. Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029 [TBL] [Abstract][Full Text] [Related]
16. The FcγR of humans and non-human primates and their interaction with IgG: implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies. Hogarth PM; Anania JC; Wines BD Curr Top Microbiol Immunol; 2014; 382():321-52. PubMed ID: 25116107 [TBL] [Abstract][Full Text] [Related]
17. Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors. Loyau J; Malinge P; Daubeuf B; Shang L; Elson G; Kosco-Vilbois M; Fischer N; Rousseau F MAbs; 2014; 6(6):1621-30. PubMed ID: 25484053 [TBL] [Abstract][Full Text] [Related]
18. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. Nechansky A; Schuster M; Jost W; Siegl P; Wiederkum S; Gorr G; Kircheis R Mol Immunol; 2007 Mar; 44(7):1815-7. PubMed ID: 17011625 [TBL] [Abstract][Full Text] [Related]